Pasithea Therapeutics Corp. (KTTA)

NASDAQ: KTTA · IEX Real-Time Price · USD
1.03
+0.03 (3.00%)
At close: Dec 2, 2022 4:00 PM
1.04
+0.01 (0.97%)
After-hours: Dec 2, 2022 6:09 PM EST
3%
Market Cap 29.54M
Revenue (ttm) 15,062
Net Income (ttm) -8.19M
Shares Out 26.55M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 33,335
Open 1
Previous Close 1
Day's Range 0.98 - 1.05
52-Week Range 0.81 - 3.35
Beta n/a
Analysts Buy
Price Target 2.35 (+128.2%)
Earnings Date n/a

About KTTA

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida. [Read more]

Industry Biotechnology
IPO Date Sep 15, 2021
Employees 3
Stock Exchange NASDAQ
Ticker Symbol KTTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for KTTA stock is "Buy." The 12-month stock price forecast is 2.35, which is an increase of 128.16% from the latest price.

Price Target
$2.35
(128.16% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time

MIAMI BEACH, Fla., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development ...

6 days ago - GlobeNewsWire

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

NEW YORK & TORONTO--( BUSINESS WIRE )--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the “Investor Group” or “we”), wh...

1 week ago - Business Wire

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Sy...

Pasithea's Chairman, Prof. Lawrence Steinman, to be Awarded Honorary Doctorate by University of Buenos Aires Pasithea's Chairman, Prof. Lawrence Steinman, to be Awarded Honorary Doctorate by University ...

1 month ago - GlobeNewsWire

Investor Group Comments on Pasithea Therapeutics' Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics

NEW YORK & TORONTO--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd.

1 month ago - Business Wire

Pasithea Therapeutics Acquires AlloMek Therapeutics

-- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor

1 month ago - GlobeNewsWire

Pasithea Therapeutics to Call Special Meeting of Stockholders

No action required by stockholders No action required by stockholders

2 months ago - GlobeNewsWire

Investor Group Sends Letter to Pasithea Therapeutics' Board of Directors

NEW YORK & TORONTO--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who ...

2 months ago - Business Wire

Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz

-- Dr. Cudkowicz is a pioneer in the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases -- MIAMI BEACH, Fla., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pasit...

2 months ago - GlobeNewsWire

Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

MIAMI BEACH, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and e...

2 months ago - GlobeNewsWire

Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics

NEW YORK & TORONTO--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who ...

2 months ago - Business Wire

Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting

NEW YORK & TORONTO--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who ...

3 months ago - Business Wire

Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Con...

-- Annual “From Laboratory to Clinic” conference, held at Trinity College, Oxford University, explores latest discoveries in immunology and molecular medicine ---- PAS002 is a proprietary DNA vaccine co...

3 months ago - GlobeNewsWire

Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting

NEW YORK & TORONTO--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who ...

3 months ago - Business Wire

Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group's Unjustified Campaign

Stockholders Should Protect Upside in Potential Groundbreaking Therapies for MS, ALS and Other Large Unmet Medical Conditions from Activist's Apparent Cash Grab

4 months ago - GlobeNewsWire

Pasithea Therapeutics Awarded a Drug Development Research Grant

-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction ---- Provides approximately U.S. $694,000 of non-dilutive funding -- MIAMI BEACH, Fla., July 14, 2022 (GLO...

4 months ago - GlobeNewsWire

Investor Group Comments on Pasithea Therapeutics' Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5

NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who together a...

5 months ago - Business Wire

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psy...

MIAMI BEACH, Fla., June 23, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new ...

5 months ago - GlobeNewsWire

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

- Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases -- Expands pipeline across Pasithea's core therapeu...

5 months ago - GlobeNewsWire

Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022

MIAMI BEACH, Fla., April 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new...

7 months ago - GlobeNewsWire

Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business...

-- Cash Balance of $52.9 million to fund operations well into 2024 ---- Initiation of a drug development program in schizophrenia ---- Initiation of a drug development program in multiple sclerosis ----...

8 months ago - GlobeNewsWire

Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Dani...

Newest member is a renowned thought leader in the identification of neurobiological mechanisms of mental illness Newest member is a renowned thought leader in the identification of neurobiological mecha...

9 months ago - GlobeNewsWire

KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today

Pasithea Therapeutics (KTTA) stock is heading higher on heavy trading Thursday even without any recent news from the biotech company. The post KTTA Stock Alert: 6 Things to Know About Pasithea Therapeut...

11 months ago - InvestorPlace

Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom

-- Expanding Pasithea Clinics footprint in London -- -- Expanding Pasithea Clinics footprint in London --

11 months ago - GlobeNewsWire

EXCLUSIVE: Pasithea Expands Its Footprint With Second Ketamine Therapy Clinic In UK

Pasithea Therapeutics Corp's (NASDAQ: KTTA) subsidiary, Pasithea Clinics, has opened its second London clinic in Marylebone, offering intravenous (IV) ketamine therapy to patients suffering from treatme...

11 months ago - Benzinga

Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada

-- Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada -- -- Treatments conducted by board-certified medical professionals --

1 year ago - GlobeNewsWire